Melatonina

Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects

J Pineal Res. 2005 Aug;39(1):12-20.
Cini G, Neri B, Pacini A, Cesati V, Sassoli C, Quattrone S, D'Apolito M, Fazio A, Scapagnini G, Provenzani A, Quattrone A.
Transcriptional downregulation of cyclin D1 is the key molecular link between melatonin and its effects on the cell cycle.
Estrogen-elicited cyclin D1

Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat

Breast Cancer Res. 2005;7(4):R470-6.
Lenoir V, de Jonage-Canonico MB, Perrin MH, Martin A, Scholler R, Kerdelhué B.
The long-term inhibition of mammary adenocarcinoma ADK promotion by a brief, preventive treatment with melatonin (10 mg/kg daily/15 days) could also reduce the risk of breast cancer induced in women by unidentified environmental factors.
Dimethylbenzanthracene (DMBA)

Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin

J Cardiovasc Pharmacol. 2005 Aug;46(2):200-10.
Kim C, Kim N, Joo H, Youm JB, Park WS, Cuong DV, Park YS, Kim E, Min CK, Han J.
Melatonin (10 mg/kg, SC for 6 days) protects against adriamycin-induced cardiotoxicity (single intraperitoneal injection of 25 mg/kg) and enhances its antitumor activity.
Adriamycin-induced cardiotoxicity

Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity

Int J Cancer. 2006 Jan 15;118(2):274-8.
Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C, Sánchez-Barceló EJ. Source
Melatonin could exert its antitumoral effects on hormone-dependent mammary tumors by inhibiting the aromatase activity of the tumoral tissue.
Aromatase inhibitor (aminoglutethimide)

Pagine

Abbonamento a RSS - Melatonina